NLRP3 and psoriasis: Co-treatment with BAY 11-7082 (a NF-κB inhibitor) attenuated psoriasis, along with reduced expressions of p-NF-κB, NLRP3, IL-1β, TNF-α, and IL-6 (Irrera et al., 2017).